info@efcni.org

Other content tagged: RSV Respiratory Syncytial Virus

New preliminary study results suggest that new RSV antibody may help reduce infant hospitalisation due to RSV

Interesting first preliminary results from the HARMONIE phase 3b trial on the efficacy of Nirsevimab against RSV (respiratory syncytial virus) infection were presented at the 41st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) in Lisbon in early May. According to these initial results, a single intramuscular dose of this new monoclonal antibody would significantly reduce the frequency of hospitalisations in infants with RSV-associated lower respiratory tract infections (LRTI), suggesting that…
Read more

Beneficial influence of breastfeeding on Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children – a systematic literature review

The Respiratory Syncytial Virus (RSV) poses a significant risk of serious infection in children worldwide, in particular in children in low-income and middle-income countries. However, previous studies indicated that breastfeeding could be a protective factor as it strengthens the immune system and protects against other serious childhood infections. A current systematic review summarises the available evidence on breastfeeding and its effects on acute lower respiratory infections which are associated with RSV. Breastfeeding is officially…
Read more

The impact of childhood RSV infection on children’s and parents’ quality of life

A Spanish study explored the loss of health-related quality of life (HRQoL) in children younger than two years after a respiratory syncytial virus (RSV) infection. Results showed an HRQoL loss of 38%, 32% and 9% during the first, second and third week after the diagnosis and a median cost of ~€600 per treated child. This type of socioeconomic evaluation could help prioritise the development of an RSV vaccine. The Respiratory Syncytial Virus (RSV) is a…
Read more